转移性脑膜瘤伴全身受累:分子、基因组与影像学特征探讨
该回顾性病例系列纳入2012至2024年间某机构2888例脑膜瘤患者,其中5例出现全身转移,包括1例2级非典型和4例3级间变性脑膜瘤。转移部位包括头皮、腮腺、椎体、肝、肺和颈部,检出MTAP、BAP1、CDKN2A/B及H3K27me3相关改变,尽管积极手术、化疗、靶向治疗和局部放疗,仍有3例进展死亡。
要点
- 高级别脑膜瘤更易发生全身转移,需警惕复发及高级别病例的随访。
- 早期分子检测或有助于识别全身转移风险患者,指导监测与治疗决策。
- 转移后生存明显缩短,需多学科协作与密切随访。
核心结论
- 颅外转移性脑膜瘤诊断和治疗挑战大,高级别脑膜瘤更易转移,早期发现转移困难。
- 对复发或高级别且携带特定突变的脑膜瘤,需多学科协作和密切随访。
研究设计与样本
- 2012至2024年单中心电子病历回顾性病例系列,共2888例脑膜瘤患者,其中5例出现转移特征。
- 复习临床资料包括影像、活检结果和手术结局,重点关注基因组细节、组织病理、疾病进展和治疗。
主要发现
- 5例转移患者中1例为2级非典型脑膜瘤,4例为3级间变性脑膜瘤。
- 转移部位为头皮1例、腮腺1例、椎体3例、肝1例、肺1例、颈部1例,影像和活检确认转移来源。
- 患者接受多次手术切除、化疗、靶向治疗(依维莫司、伊沙佐米、他泽司他)和局部放疗。
- 检出MTAP、BRCA-1相关蛋白-1、CDKN2A/B和H3K27me3突变。
- 尽管积极治疗,3例疾病进展死亡,其余对治疗部分缓解;诊断后平均生存107个月,转移后降至24个月。
关键数值与推荐
- 2888例脑膜瘤患者中5例发生全身转移。
- 转移部位包括头皮1例、腮腺1例、椎体3例、肝1例、肺1例、颈部1例。
- 诊断后平均生存107个月,转移后平均生存24个月。
临床怎么用
- 对高级别或复发脑膜瘤应保持对全身转移的警惕,结合影像与活检确认。
- 可考虑早期分子检测识别转移风险,指导监测策略和治疗选择。
- 转移性病例需多学科综合治疗,包括手术、化疗、靶向治疗和局部放疗。
局限性
- 为单中心回顾性病例系列,转移病例仅5例,样本量小。
- 原文未报告对照设计、前瞻性随访或统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Meningiomas are typically benign, slow-growing tumors localized to the cranial or spinal regions, with less than 1% metastasizing systemically, posing a serious clinical challenge. This case series adds critically needed data to broaden existing knowledge and demonstrates that early molecular profiling may identify patients at risk for systemic metastasis, informing surveillance strategies and treatment decisions. METHODS: Between 2012 and 2024, we retrospectively reviewed patients with meningiomas from our institution's electronic medical record. Clinical data, including imaging, biopsy results, and surgical outcomes, were reviewed, focusing on genomic details, histopathology, disease progression, and treatment. RESULTS: We found 2888 patients with meningiomas, 5 of whom developed metastatic features, one Grade 2 atypical meningioma, and 4 Grade 3 anaplastic meningiomas. Metastases occurred to the scalp (1 case), parotid gland (1 case), vertebra (3 cases), liver (1 case), lungs (1 case), and neck (1 case). Imaging (computed tomography, magnetic resonance imaging, positron emission tomography-computed tomography) and biopsies confirmed origin of metastases. These patients received multiple surgical resections, chemotherapy, targeted therapy (everolimus, ixazomib, and tazemetostat), and localized radiation. Mutations in MTAP, BRCA-1-associated protein-1, CDKN2A/B, and H3K27me3 were identified. Despite aggressive treatment, 3 patients experienced disease progression and died, while the others showed partial response to therapy. Survival averaged 107 months from diagnosis, dropping to 24 months postmetastasis. CONCLUSIONS: Extra-central nervous system metastatic meningiomas pose significant diagnostic and therapeutic challenges. High-grade meningiomas are more likely to metastasize; early detection of metastatic spread is challenging. Our findings highlight the need for a multidisciplinary approach with close follow-up, especially in recurrent or high-grade meningiomas with distinct mutations.
引用
- Sulman M, Del Bosque A, Cantillo D, et al. Metastatic Meningioma with Systemic Involvement: Discussion of Molecular, Genomic, and Radiological Features. World Neurosurg. 2026. PMID: 42107879. doi:10.1016/j.wneu.2026.125041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。